Cover Image

Pegylated interferon-α2a in cutaneous T-cell lymphoma: a multicenter retrospective data analysis with 70 patients = Pegyliertes Interferon-α2a bei kutanen T-Zell-Lymphomen : eine multizentrische retrospektive Datenanalyse mit 70 Patienten

Background Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative trea...

Full description

Saved in:
Bibliographic Details
Main Authors: Hansen-Abeck, Inga (Author) , Geidel, Glenn (Author) , Abeck, Finn Frederik (Author) , Kött, Julian (Author) , Cankaya, Rohat (Author) , Dobos, Gábor (Author) , Mitteldorf, Christina (Author) , Nicolay, Jan Peter (Author) , Albrecht, Jana Dorothea (Author) , Menzer, Christian (Author) , Livingstone, Elisabeth (Author) , Mengoni, Miriam (Author) , Braun, Andreas (Author) , Wobser, Marion (Author) , Klemke, Claus-Detlev (Author) , Tratzmiller, Sabine (Author) , Assaf, Chalid (Author) , Terheyden, Patrick (Author) , Klespe, Kai-Christian (Author) , Schneider, Stefan W. (Author) , Booken, Nina (Author)
Format: Article (Journal)
Language:English
German
Published: November 2024
In: Journal der Deutschen Dermatologischen Gesellschaft
Year: 2024, Volume: 22, Issue: 11, Pages: 1489-1497
ISSN:1610-0387
DOI:10.1111/ddg.15511
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/ddg.15511
Verlag, kostenfrei, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.15511
Get full text
Author Notes:Inga Hansen-Abeck, Glenn Geidel, Finn Abeck, Julian Kött, Rohat Cankaya, Gabor Dobos, Christina Mitteldorf, Jan P. Nicolay, Jana D. Albrecht, Christian Menzer, Elisabeth Livingstone, Miriam Mengoni, Andreas D. Braun, Marion Wobser, Claus-Detlev Klemke, Sabine Tratzmiller, Chalid Assaf, Patrick Terheyden, Kai-Christian Klespe, Stefan W. Schneider, Nina Booken
Description
Summary:Background Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative treatment, even though it is not approved for the treatment of CTCL. The aim of this multicentre study was to generate comprehensive data on the efficacy and tolerability of pegIFN-α2a in the treatment of CTCL. Patients and Methods A multicenter retrospective study was conducted with 70 patients with CTCL from twelve German skin centers. Results In total, 70 patients were included in the study, with 57.2% male and a mean age of 58.8 ± 14.9 years. Mycosis fungoides was present in 71.4% of cases and Sézary Syndrome in 28.6%. An overall response rate of 55.2% was observed with pegIFNα-2a therapy. In 50% of cases, therapy was discontinued after 63.6 ± 33.5 weeks. The most common reason for discontinuation was adverse events, which occurred in 68.6% of cases and which were classified as severe in 29.2%. Blood count changes, fatigue and liver toxicity occurred most frequently. Conclusions Our analysis provides comprehensive data on the efficacy and tolerability of pegIFNα-2a therapy in patients with CTCL. In terms of response rates and side effect profile, pegIFNα-2a appears to be comparable to IFN-α2a therapy.
Item Description:Erstmals veröffentlicht: 02. Oktober 2024
Gesehen am 07.01.2025
Physical Description:Online Resource
ISSN:1610-0387
DOI:10.1111/ddg.15511

Similar Items